Kalmantis T, Kalmanti M, Vassilaki M, Spandidos D A
Second Department of Internal Medicine, Hematology-Oncology, University of Athens, Hippokration General Hospital, Greece.
Anticancer Res. 1993 Jul-Aug;13(4):1103-6.
Mutation of the ras oncogenes is the most commonly detected molecular abnormality in acute myelogenous leukemia and myelodysplastic syndromes (MDS). This molecular event may either be acquired by different subclones or by all malignant cells. The availability of the ras p21 monoclonal antibody Y13 259 makes possible the direct study of the distribution of the ras gene product in human malignant cells. The bone marrow smears from 41 patients with MDS were analysed by two independent observers after treatment with MoAb Y13 259, biotinylated goat antirat IgG, streptavidin, peroxidase and staining with diaminobenzidine. A high proportion of strongly positive smears was found among patients with MDS. This positivity was found in 25% of refractory anemia, in 80% of the refractory anemias with excess of blasts, and in 90% of those in transformation, while all 7 cases with chronic myelomonocytic leukemia were found positive. The percentage of positivity may suggest that activation of ras oncogene in associated with disease progression.
ras癌基因的突变是急性髓性白血病和骨髓增生异常综合征（MDS）中最常检测到的分子异常。这种分子事件可能由不同的亚克隆或所有恶性细胞获得。ras p21单克隆抗体Y13 259的可用性使得直接研究ras基因产物在人类恶性细胞中的分布成为可能。41例MDS患者的骨髓涂片在经单克隆抗体Y13 259、生物素化山羊抗大鼠IgG、链霉亲和素、过氧化物酶处理并用二氨基联苯胺染色后，由两名独立观察者进行分析。在MDS患者中发现高比例的强阳性涂片。在25%的难治性贫血、80%的伴有原始细胞增多的难治性贫血以及90%的转化期患者中发现这种阳性，而所有7例慢性粒单核细胞白血病患者均呈阳性。阳性百分比可能表明ras癌基因的激活与疾病进展相关。
